Navigation Links
New Study Suggests Better Patient Outcomes with CYPHER,Sirolimus-Eluting Coronary Stent than with Taxus Stent in,Real-World Clinical Settings

Registry Analysis Published in Journal Heart Finds Taxus Stent, Implantation of Multiple Stents and Small Vessel Size To Be Independent Predictors of Need for Another Procedure


MIAMI LAKES, Fla., June 4, 2007 /PRNewswire via COMTEX News Network/ -- An analysis of data from the Western Denmark Heart Registry found that patients who received the CYPHER(R) Sirolimus-eluting Coronary Stent to open a clogged artery were less likely to need another procedure at that same lesion site (a clinical event called target lesion revascularization or TLR) than patients who received a Taxus Stent. The analysis was published in the June 1 issue of the journal Heart.

The authors of the analysis sought to identify risk factors for symptom- driven TLR when patients were treated with the CYPHER(R) Stent or the Taxus Stent in a real-world scenario. From Jan. 1, 2003 to May 18, 2005, 4,432 patients in Western Denmark were treated with a drug-eluting stent (CYPHER(R) Stent: 2,728 patients; Taxus Stent: 1,704 patients). Use of a Taxus Stent (odds ratio of 1.43; p=0.022), implantation of multiple stents per lesion (odds ratio of 1.62; p=0.008) and stent implantation in small vessels (odds ratio of 1.42; p=0.049) were found to be independent predictors of the need for TLR at nine months after the procedure.

"The major new finding of this study was that the use of the Taxus Stent was an independent predictor of TLR for a real-world population of patients treated with the CYPHER(R) Stent and the Taxus Stent," said Michael Maeng, M.D., Principal Investigator, from Aarhus University Hospital, Denmark.

When the lesions were divided into subgroups according to vessel size, the CYPHER(R) Stent yielded a 20 percent relative reduction of TLR in large vessels (2.4 percent versus 3.0 percent in arteries with a reference diameter equal to or greater than 2.8 mm; p=not significant) and a 40 percent relative reductio
'"/>




Page: 1 2 3

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Clinical Study Shows Regenecare Relieves Pain and Itching of Skin Rashes Caused by Widely Used Cancer Drugs
3. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. Reaction to Avandia Warnings Stronger Among Internists Than Endocrinologists, According to Study by GfK Market Measures
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
8. Protox Announces Positive Clinical Data from Prostate Cancer Study
9. International ENDORSE Study Shows That the Majority of Hospitalized Patients Surveyed are at Risk for VTE and Many do not Receive Recommended VTE prophylaxis
10. New Study Shows That Extending Prophylaxis With Clexane / Lovenox (enoxaparin Sodium Injection) to 5 Weeks is More Effective Than 10 Days for Reducing the Risk of Venous Thromboembolism (VTE) in Acutely ill Medical Patients With Reduced Mobility
11. Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea

Post Your Comments:
(Date:11/6/2009)...Newswire-FirstCall/ -- NuVasive, Inc. (Nasdaq: NU...ng products for minimally disruptive surgical trea...ent of Michael J. Lambert as Executive Vice Presid...r 9, 2009. The Company also announced several oth...el will be an excellent complement to the NuVasive...
(Date:11/6/2009)...ov. 6 With his proposed health car...sights on cutting name-brand prescription drug cos...to the "Part D" coverage gap, universally known as...otential cost-cutting and feel it,s a promising st...werful lobbyists want a revised program that compl...
(Date:11/6/2009)...wswire-FirstCall/ -- Cyberonics, Inc. (Nasdaq: CY...financial results for the second quarter ended Oct...2010 on Wednesday, November 18, 2009 at 5:00 PM ES...discuss those results on Thursday, November 19, 20... Quarter Results Conference Call Instructions ,...
Breaking Medicine Technology:NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 2NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 3NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 4NuVasive Appoints New Chief Financial Officer and Announces Additional Management Updates 5Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 2Obama Healthcare Reforms Fall Short, but Betterthanmedicare.com Closes the 'Donut Hole' 3Cyberonics Announces Conference Call to Discuss Fiscal Year 2010 Second Quarter Financial Results 2Biochemical on switch could solve protein purification challenge 10485 1Biochemical on switch could solve protein purification challenge 10485 2General anesthetics lead to learning disabilities in animal models 59954 1General anesthetics lead to learning disabilities in animal models 59954 2General anesthetics lead to learning disabilities in animal models 59954 3Study reveals an increase in long term antidepressant drug use 59950 1
...h, MIAMI and PALM BEACH, Fla., Sept. 2 September...Knife Centers of Miami and,Palm Beach announce a r...out surgery and long treatment courses of radiatio...er affecting men in the US., Morse CyberKnife CEO...at are diagnosed early on, CyberKnife radiosurgery...
...ensity and Secondary Efficacy ...all and Webcast Wednesday, September 3rd at ...GO, Sept. 2 Neurocrine Biosciences,Inc. (Nasdaq: ...cy results,from its third Phase II clinical trial ...nadotropin-Releasing Hormone (GnRH) receptor antag...
Other Medicine Technology:Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 2Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 3Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 4Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 5Neurocrine Biosciences Announces Successful Elagolix PETAL Study in Endometriosis 6
(Date:11/9/2009)... Doctor house calls now available in New ... New York, NY (PRWEB) November 9, ...an, will now offer routine house calls to resident...able to request a house call by calling the offi...bregman.com . The convenience of being able to see...
(Date:11/9/2009)... Leading U.S. air ambulance company now t...AMI accreditation and Department of Defense approv...EB) November 9, 2009 -- AirMed International, the ...y it has earned full accreditation from the Europe...tuttgart, Germany, based non-profit association of...
(Date:11/9/2009)...Nov. 9 Davis Bregman , a pain m...alls to residents of Manhattan in New York City. ...by calling the office at 212-918-1629 or sending a...e of being able to see the doctor in the less stre...is new way of seeing most patients. The service w...
(Date:11/8/2009)..., Nov. 8 Jon O,Brien, p...wing statement about the passage of HR 3962: ,...can voters a lot about core values. We in the proc...eking to overcome the struggles ordinary Americans...many cannot afford basic healthcare or have to cho...
(Date:11/8/2009)... UCW Academy of Health holds open house a...ria, BC (Vocus) November 8, 2009 -- UCW Academy of...n British Columbia’s health care industry to... November 25, 2009. , ,UCW Academy of Health, whi..., nursing and social services, designs its program...
Breaking Medicine News(10 mins):Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:AirMed International, Top U.S. Air Ambulance, Receives EURAMI Accreditation 2Health News:Davis Bregman MD Now Offering House Calls in Manhattan 2Health News:Catholics for Choice Statement on Healthcare Reform Bill 2Health News:College Invites Public to Explore Career Options in Health Care 2
...er phobia, study finds , , MONDAY, May 5 (...ptions about their children,s fever and overtreat ...y shows. , Parents, ethnicity may also play a role... fix it, so every pediatrician must have the fever...
...ncer patients who have a prior history of mood and...periencing posttraumatic stress disorder following...y of 74 breast cancer patients at the Ohio State U...e as likely as breast cancer patients without the ...
...or Edward G.,Rendell today urged the Senate to imm...PA ABC) for the uninsured now that an analysis sho... "The financial analysis released today by the Gov...le health insurance,through PA ABC; and continue t...
...n Promotes Cancer Screenings and Early ... the help of Texas Oncology this,Mother,s Day, giv...t that,will last: good health. Texas Oncology make...l way to stay healthy., The Mother,s Day Screenin...
...atter of debate, experts say , , MONDAY, M...emiums increase, so do the rates of Caesarean sect...mall snapshot of the association, drawing on data ... higher malpractice rates boost the C-section rate...
...y of Texas Medical Branch at Galveston researchers...new weapon against respiratory syncytial virus, th...he United States. , In an effort to find an effec...uses to replicate, or copy itself, within cells. B...
Other Medicine News:Health News:Ethnicity Plays Role in Parents' Treatment of Childhood Fever 2Health News:Anxiety, mood disorders put cancer patients at risk for PTSD 2Health News:PA Governor Says Financial Analysis Shows Nothing Stands in Way of Senate Action to Help Pennsylvania's Uninsured 2Health News:Texas Oncology Reminds Women 'You're the Best, Get the Tests' 2Health News:Texas Oncology Reminds Women 'You're the Best, Get the Tests' 3Health News:Malpractice Premiums, Rate of C-Sections Rise Together 2Health News:Malpractice Premiums, Rate of C-Sections Rise Together 3Health News:New agent strikes at respiratory syncytial virus replication 2
Single Tantalum Clip (50 Style)
Silicone Strip (41 Style)
Charles Silicone Tire (282 Style)
Asymmetrical Silicone Tire (276 Style)
Medicine Products: